ICN Pharmaceuticals, Inc.

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of the Earliest Event Reported: May 5, 2003

Date of Report: May 5, 2003

 

 

 

ICN Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

  

1-11397

  

33-0628076

(State or other jurisdiction of

incorporation or organization)

  

(Commission

file number)

  

(I.R.S. Employer

Identification No.)

 

3300 Hyland Avenue

Costa Mesa, California 92626

(Address of principal executive offices) (Zip code)

 

(714) 545-0100

(Registrant’s telephone

number, including area code)

 

 

Item 7. Financial Statements and Exhibits.

 

(c) Exhibits

 

Exhibit No.

   

Description

  99.1

   

Press Release dated May 5, 2003

 

Item 9. Regulation FD Disclosure.

 

The following information is furnished pursuant to Item 12, “Disclosure of Results of Operations and Financial Conditions.”

 

On May 5, 2003, ICN Pharmaceuticals, Inc. issued a press release announcing its first fiscal quarter results ended March 31, 2003 and will hold a conference call on such date. The press release is attached as Exhibit 99.1.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, ICN Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:    May 5, 2003

          

ICN PHARMACEUTICALS, INC.

               

/s/    Robert W. O’Leary        

               

Chairman and Chief Executive Officer